Laboratory of Veterinary Pharmacology, Faculty of Veterinary Medicine, Okayama University of Science, Imabari, Ehime, 7948555, Japan.
Laboratory of Applied Microbiology, Faculty of Life Science, Okayama University of Science, Okayama, 7000005, Japan.
Sci Rep. 2023 Sep 14;13(1):15197. doi: 10.1038/s41598-023-42377-7.
One feature of hypertension is a microbial imbalance with increased intestinal permeability. In this study, we examined whether an alteration in the microbiota affects blood pressure and intestinal permeability in spontaneously hypertensive rats (SHRs). We performed a 16S metagenome analysis of feces from 10- to 15-week-old SHRs using a synthetic long-read sequencing approach, and found a candidate for the microbiome treatment, Ligilactobacillus murinus (L. murinus), that was robustly decreased. Oral administration of L. murinus to SHRs for 2 weeks significantly inhibited blood pressure elevation and improved endothelium-dependent vasodilation but did not attenuate enhanced vascular contraction in SHR mesenteric arteries. The proximal colon of SHRs exhibited increased intestinal permeability with decreased levels of the tight junction protein claudin 4, morphological changes such as decreased intestinal crypts and elevated TNF-α levels, which was reversed by treatment with L. murinus. Consistent with these intestinal phenotypes, plasma lipopolysaccharides levels were elevated in SHR but decreased following L. murinus administration. We concluded that oral administration of L. murinus to SHRs exerts protective effects on intestinal permeability via restoration of claudin 4 expression and reversal of morphologic disorder, which may improve low-grade endotoxemia and thus reduce development of hypertension via recovery of endothelial vasodilating functions.
高血压的一个特征是微生物失衡,肠道通透性增加。在这项研究中,我们研究了微生物群的改变是否会影响自发性高血压大鼠(SHR)的血压和肠道通透性。我们使用合成长读测序方法对 10-15 周龄 SHR 的粪便进行了 16S 宏基因组分析,发现了一种候选的微生物组治疗药物,即乳酸乳球菌(L. murinus),其丰度显著降低。将 L. murinus 口服给予 SHR 2 周可显著抑制血压升高和改善内皮依赖性血管舒张,但不能减轻 SHR 肠系膜动脉增强的血管收缩。SHR 的近端结肠表现出肠道通透性增加,紧密连接蛋白 Claudin 4 水平降低,形态学变化如肠隐窝减少和 TNF-α水平升高,这些变化可通过 L. murinus 治疗逆转。与这些肠道表型一致,SHR 的血浆脂多糖水平升高,但给予 L. murinus 后降低。我们得出结论,口服 L. murinus 对 SHR 的肠道通透性具有保护作用,可通过恢复 Claudin 4 的表达和逆转形态异常来实现,这可能通过恢复内皮血管舒张功能来改善低水平内毒素血症,从而降低高血压的发生。